Back

The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Novel insight into heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Esteban Fernandez

Severo Ochoa Hospital, Leganes (Spain)

6 More presentations in this session

Presentation thumbnail
Prognostic impact of residual symptoms at discharge in patients hospitalized for worsening heart failure
Doctor Y. Yamada (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Current status and characteristics of advance directives in Japanese patients with acute heart failure
Doctor K. Takabayashi (Shiga, JP)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of Vericiguat 5mg initiation in combination with guideline-directed medical therapy in the treatment of Heart failure with reduced ejection fraction
Professor Y. Wang (Changchun, CN)
Abstract Slides Video
Presentation thumbnail
Oral acetazolamide in acute heart failure: effects on renal function and clinical outcomes
Mr J. Gomez Rosero (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Characteristics and treatment of patients with heart failure followed in heart failure units in Spain. Differences according to the type of unit.
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insight into heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes
thumbnail
Congress Presentation
Early in-hospital initiation of SGLT2 inhibitors in acute decompensated heart failure
thumbnail
Congress Presentation
Real-world impact of early quadruple therapy in HFrEF: a comparative analysis of sequential vs. simultaneous approaches

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources